Review Lentiviral Vectors and Antiretroviral Intrinsic Immunity
暂无分享,去创建一个
[1] B. Cullen,et al. Differential Sensitivity of Murine Leukemia Virus to APOBEC3-Mediated Inhibition Is Governed by Virion Exclusion , 2005, Journal of Virology.
[2] M. Löchelt,et al. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] W. Greene,et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.
[4] B. Cullen,et al. Inhibition of a Yeast LTR Retrotransposon by Human APOBEC3 Cytidine Deaminases , 2005, Current Biology.
[5] T. Heidmann,et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses , 2005, Nature.
[6] R. König,et al. APOBEC3B and APOBEC3C Are Potent Inhibitors of Simian Immunodeficiency Virus Replication* , 2004, Journal of Biological Chemistry.
[7] R. Blasco,et al. Susceptibility of different leukocyte cell types to Vaccinia virus infection , 2004, Virology Journal.
[8] D. Trono,et al. The Innate Antiretroviral Factor APOBEC3G Does Not Affect Human LINE-1 Retrotransposition in a Cell Culture Assay* , 2004, Journal of Biological Chemistry.
[9] M. Scharff,et al. The role of activation-induced cytidine deaminase in antibody diversification, immunodeficiency, and B-cell malignancies. , 2004, The Journal of allergy and clinical immunology.
[10] V. Pathak,et al. Human Apolipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G (APOBEC3G) Is Incorporated into HIV-1 Virions through Interactions with Viral and Nonviral RNAs* , 2004, Journal of Biological Chemistry.
[11] Jianzhi Zhang,et al. Rapid evolution of primate antiviral enzyme APOBEC3G. , 2004, Human molecular genetics.
[12] W. Brown,et al. APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo , 2004, Current Biology.
[13] L. Kleiman,et al. The Interaction between HIV-1 Gag and APOBEC3G* , 2004, Journal of Biological Chemistry.
[14] A. Takaori-Kondo,et al. APOBEC3G Targets Specific Virus Species , 2004, Journal of Virology.
[15] M. Malim,et al. APOBEC-Mediated Editing of Viral RNA , 2004, Science.
[16] M. Emerman,et al. Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G , 2004, PLoS biology.
[17] Matthew J. Stephens,et al. Global effect of PEG-IFN-α and ribavirin on gene expression in PBMC in vitro , 2004 .
[18] Boro Dropulic,et al. Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance , 2004, Journal of Virology.
[19] B. Cullen,et al. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins , 2004, The EMBO journal.
[20] Richard Carroll,et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] Takeshi Kurosu,et al. Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication , 2004, Journal of Virology.
[22] D. Trono,et al. A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action* , 2004, Journal of Biological Chemistry.
[23] Markus G. Manz,et al. Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.
[24] D. Trono,et al. Inhibition of Hepatitis B Virus Replication by APOBEC3G , 2004, Science.
[25] N. Landau,et al. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] B. Cullen,et al. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] Yunkai Yu,et al. Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.
[28] M. Malim,et al. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif , 2003, Nature Medicine.
[29] S. Fan,et al. Molecular therapeutics of HBV. , 2003, Current gene therapy.
[30] R. König,et al. Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif , 2003, Cell.
[31] Hui Zhang,et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.
[32] Gersende Caron,et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.
[33] M. Malim,et al. DNA Deamination Mediates Innate Immunity to Retroviral Infection , 2003, Cell.
[34] Reuben S Harris,et al. Immunity through DNA deamination. , 2003, Trends in biochemical sciences.
[35] F. Clavel,et al. Hypermutation of HIV-1 DNA in the Absence of the Vif Protein , 2003, Science.
[36] F. Alt,et al. Transcription-targeted DNA deamination by the AID antibody diversification enzyme , 2003, Nature.
[37] J. Wedekind,et al. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. , 2003, Trends in genetics : TIG.
[38] D. Trono,et al. Modalities of Interleukin-7-Induced Human Immunodeficiency Virus Permissiveness in Quiescent T Lymphocytes , 2002, Journal of Virology.
[39] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[40] I. Dunham,et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. , 2002, Genomics.
[41] T. Waters,et al. Thymine-DNA glycosylase and G to A transition mutations at CpG sites. , 2000, Mutation research.
[42] M. Shapiro,et al. Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.
[43] M. Malim,et al. Evidence for a newly discovered cellular anti-HIV-1 phenotype , 1998, Nature Medicine.
[44] Navid Madani,et al. An Endogenous Inhibitor of Human Immunodeficiency Virus in Human Lymphocytes Is Overcome by the Viral Vif Protein , 1998, Journal of Virology.
[45] Y. Korin,et al. Progression to the G1b Phase of the Cell Cycle Is Required for Completion of Human Immunodeficiency Virus Type 1 Reverse Transcription in T Cells , 1998, Journal of Virology.
[46] J. Taylor,et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. Trono,et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells , 1993, Journal of virology.
[48] J. Sodroski,et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes , 1992, Journal of virology.
[49] P. Tiollais,et al. Hepatitis B virus. , 1991, Scientific American.
[50] Jerome A. Zack,et al. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.
[51] J. Stoye,et al. Retrotransposons, Endogenous Retroviruses, and the Evolution of Retroelements , 1997 .